AbbVie's zumilokibart clears Phase II with long-interval dosing signal
AbbVie reports its injectable biologic zumilokibart cleared Phase II, with a profile the company says could support quarterly or twice-yearly maintenance dosing.
Topic
Phase Ii
Topic
Phase Ii
Tulisokibart posts first positive Phase II anti-TL1A read-out
Merck's tulisokibart produced the first positive Phase II efficacy data for an anti-TL1A antibody in a dermatologic indication, o…